Chairman and Professor Department of Obstetrics and Gynecology, University of Chicago Medicine
Obstetrics & Gynecology
Dr. Ernst R. Lengyel, MD
|
|
Give Review
Ernst R. Lengyel, MD practices Obstetrics & Gynecology. He received awards:"America's Top Doctors", "Chicago Magazine: Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Chicago Magazine - Women's Health" and "Super Doctor". Ernst Lengyel is also published. He has 89 publications published. The lastest publication: "Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Rethinking ovarian Cancer II: reducing mortality from high-grade serous ovarian Cancer.
- Microenvironment-induced downregulation of miR-193b drives ovarian Cancer metastasis.
- Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.
- Old drug, new trick: Repurposing metformin for gynecologic Cancers?
- WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian Cancer.
- Three-dimensional modeling of ovarian Cancer.
- Expression of the Homeobox Gene HOXA9 in Ovarian Cancer Induces Peritoneal Macrophages to Acquire an M2 Tumor-Promoting Phenotype.
- Epithelial ovarian Cancer experimental models.
- Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.
- Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube Carcinoma.
- Adipose tissue and adipocytes support tumorigenesis and metastasis.
- MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer.
- The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous Carcinoma.
- Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report.
- Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor g...
- Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia.
- Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series...
- Quantitative high throughput screening using a primary Human three-dimensional organotypic culture predicts in vivo efficacy.
- The effect of smoking on the presence of antinuclear antibodies and on the morphology of lymphocytes in aged subjects.
- In vitro modulation of Human melanoma cell invasion and proliferation by all-trans-retinoic acid.
- JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation.
- Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid Cancer patients.
- [The clinical importance of keratin 18 in breast Cancer].
- Keratin expression reveals mosaic differentiation in Vaginal epithelium.
- UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
- Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast Cancer.
- Ras regulation of urokinase-type plasminogen activator.
- Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase...
- RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.
- Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube Cancer.
- beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.
- Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2.
- Induction of M(r) 92,000 type IV collagenase expression in a squamous cell Carcinoma cell line by fibroblasts.
- Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.
- Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors.
- PDGFR-alpha as a potential therapeutic target in Uterine sarcomas.
- Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia.
- Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell Carcinoma cell line.
- Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
- Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding...
- Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian Cancer cells.
- Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras.
- Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
- Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian Cancer.
- Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian Cancer invasion and metastasis.
- Elevated urokinase-type plasminogen activator receptor expression in a colon Cancer cell line is due to a constitutively activated extracellular signal-regulated kinas...
- Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades.
- Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene.
- Rac1 in human breast Cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.
- Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced o...
- Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation.
- Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the Human genome.
- C-Met overexpression in node-positive breast Cancer identifies patients with poor clinical outcome independent of Her2/neu.
- Dosimetric predictors of acute hematologic toxicity in Cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
- Ovarian Cancer development and metastasis.
- CD95 promotes tumour growth.
- An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian Cancer metastasis.
- The Müllerian HOXA10 gene promotes growth of Ovarian surface epithelial cells by stimulating epithelial-stromal interactions.
- {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian Cancer.
- Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian Cancer metastasis.
- Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on Ovarian carcinogenesis in genetically engineered mice.
- The molecular signature of endometriosis-associated endometrioid ovarian Cancer differs significantly from endometriosis-independent endometrioid ovarian Cancer.
- Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation.
- Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation.
- MMP-2 functions as an early response protein in ovarian Cancer metastasis.
- A special key for unlocking the door to targeted therapies of breast Cancer.
- Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian Cancer.
- A novel multipurpose monoclonal antibody for evaluating Human c-Met expression in preclinical and clinical settings.
- The miR-200 family determines the epithelial phenotype of Cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.
- Loss of E-cadherin promotes ovarian Cancer metastasis via alpha 5-integrin, which is a therapeutic target.
- The initial steps of ovarian Cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.
- Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
- Let-7 prevents early Cancer progression by suppressing expression of the embryonic gene HMGA2.
- Let-7 expression defines two differentiation stages of Cancer.
- Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian Cancer cells to...
- Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal Cancer.
- Tyrosine kinase mutations in human Cancer.
- c-Met overexpression is a prognostic factor in ovarian Cancer and an effective target for inhibition of peritoneal dissemination and invasion.
- Relationship of type II diabetes and metformin use to ovarian Cancer progression, survival, and chemosensitivity.
- Adipocytes promote ovarian Cancer metastasis and provide energy for rapid tumor growth.
- The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on Ovarian carcinogenesis.
- Rethinking ovarian Cancer: recommendations for improving outcomes.
- FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas.
- Let-7 modulates acquired resistance of ovarian Cancer to Taxanes via IMP-1-mediated stabilization of MDR1.
- Foretinib (GSK1363089), an orally available multi-kinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian Cancer metastasis.
- Targeting the urokinase plasminogen activator receptor inhibits ovarian Cancer metastasis.
- Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor.
- A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial Ovarian or primary p...
Procedures Preformed
- Abdominal Hysterectomy With Robotic Assistance
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Destruction or Excision of Vaginal Lesions
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Chicago Magazine - Women's Health
- Super Doctor
Education
-
Ludwig Maximilian University of Munich Faculty of Medicine
Hospital
-
University of Chicago Medical Center -
MacNeal Hospital -
Mercy Hospital and Medical Center
Drug Facts
| NPI NUMBER | 1447296306 | |
| NPPES Provider LastName | LENGYEL | |
| NPPES Provider FirstName | ERNST | |
| NPPES Provider ZIPCode | 606371447 | |
| NPPES Provider State | IL | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 95.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447296306 |
| Last Name Of The Provider | LENGYEL |
| First Name Of The Provider | ERNST |
| View All |
Similar Doctors
|
|
Dr. Edgardo L. Yordan Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hector A. Marino, MD |
|
Dr. Amalendu Majumdar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Freidoon Azizi Facog Facs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francesca L. Facco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur L. Herbst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diljeet K. Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dana R. Gossett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie L. Barton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mac H. Scott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christy A. Beyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Kosanovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Romina Kee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kemi M. Doll, MD |
|
|
Dr. Lisa M. Oldham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura R. Matthews, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nuriya D. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ketura P. Wisner, DO |